ArticleMolecular and cellular biochemistry2007
Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells.
Article in Molecular and cellular biochemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 83 citations in OpenAlex.
- Underlying Mechanisms of Osteoporosis in the Context of Multimorbidity: Clinical Challenges and Management Strategies.Nutrients · 2026Review
- Association of skin-advanced glycation end products, IMT complex, and bone mineral density in patients with type 1 diabetes.Frontiers in endocrinology · 2025Article
- Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial CaAutophagy · 2024Article
- The analgesic effects of insulin and its disorders in streptozotocin-induced short-term diabetes.Physiological reports · 2024Article
- Synergistic effect of metformin and vitamin DRegenerative therapy · 2024Article
- Low Bone Turnover Associates With Lower Insulin Sensitivity in Newly Diagnosed Drug-Naïve Persons With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2023Article
- Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes.Frontiers in endocrinology · 2022Article
- Native Collagen II Relieves Bone Impairment through Improving Inflammation and Oxidative Stress in Ageing db/db Mice.Molecules (Basel, Switzerland) · 2021Article
- Glucose Metabolism in Osteoblasts in Healthy and Pathophysiological Conditions.International journal of molecular sciences · 2021Review
- Can fingernail quality predict bone damage in Type 2 diabetes mellitus? a pilot study.PloS one · 2021Article
- Age-Influenced Receptors of Advanced Glycation End Product Overexpression Associated With Osteogenic Differentiation Impairment in Patients With Type 2 Diabetes.Frontiers in endocrinology · 2021Article
- Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature.Journal of the Endocrine Society · 2019Review
- Impact of Diabetes Mellitus on Bone Health.International journal of molecular sciences · 2019Review
- Article
- Diabetes Mellitus-induced Bone Fragility.Internal medicine (Tokyo, Japan) · 2018Article
- Bone Tissue Collagen Maturity and Mineral Content Increase With Sustained Hyperglycemia in the KK-Ay Murine Model of Type 2 Diabetes.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018Article
- Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFScience (New York, N.Y.) · 2017Article
- Role of Galectin-3 in Bone Cell Differentiation, Bone Pathophysiology and Vascular Osteogenesis.International journal of molecular sciences · 2017Review
- Advanced Glycation End Products, Diabetes, and Bone Strength.Current osteoporosis reports · 2016Review
- miR-223 contributes to the AGE-promoted apoptosis via down-regulating insulin-like growth factor 1 receptor in osteoblasts.Bioscience reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Advanced glycation end products (AGEs) have been proposed as the pathological mechanisms underlying diabetic chronic complications. They may also play a role in the pathogenesis of diabetic osteopenia, although their mechanisms of action remain unclear. We investigated the protein (immunofluorescence) and gene expression (realtime RT-PCR) of two receptors for AGEs, RAGE and galectin-3, as well as their regulation by AGEs, and the apoptotic effect on osteoblast-like cells (UMR106 and MC3T3E1) in culture. AGEs up-regulated the expression of RAGE and galectin-3 in both cells lines. These effects were accompanied by an increase in the corresponding mRNA in the non-tumoral MC3T3E1 but not in the osteosarcoma UMR106 cells. Finally, we demonstrated that a 24 h exposure to AGEs induced apoptosis in both cell lines. Thus, AGEs-receptors may play important roles in the bone alterations described in aging and diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.